Status:
COMPLETED
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer
Lead Sponsor:
Bayer
Conditions:
Breast Neoplasms
Breast Cancer, Metastatic
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether the study drug is effective and safe in the treatment of patients with metastatic breast cancer
Detailed Description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Eligibility Criteria
Inclusion
- Metastatic breast cancer
- No previous treatment with taxanes, and vinca alkaloids
- Use of highly effective birth control methods in females of child-bearing potential
Exclusion
- More than 2 previous chemotherapies
- Previous participation in another trial within the last 4 weeks
- Breast feeding
- Active infections
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT00288249
Start Date
December 1 2005
End Date
January 1 2009
Last Update
December 2 2014
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Vienna, Vienna, Austria, 1090
2
Vienna, Vienna, Austria, 1100
3
Brasschaat, Belgium, 2930
4
Plovdiv, Bulgaria, 4001